Antitumor activity of amivantamab (Jnj-61186372), an egfr–met bispecific antibody, in diverse models of egfr exon 20 insertion–driven nsclc

Jiyeon Yun, Soo Hwan Lee, Seok Young Kim, Seo Yoon Jeong, Jae Hwan Kim, Kyoung Ho Pyo, Chae Won Park, Seong Gu Heo, Mi Ran Yun, Sangbin Lim, Sun Min Lim, Min Hee Hong, Hye Ryun Kim, Meena Thayu, Joshua C. Curtin, Roland E. Knoblauch, Matthew V. Lorenzi, Amy Roshak, Byoung Chul Cho

Research output: Contribution to journalArticlepeer-review

34 Citations (Scopus)

Abstract

EGFR exon 20 insertion driver mutations (Exon20ins) in non–small cell lung cancer (NSCLC) are insensitive to EGFR tyrosine kinase inhibitors (TKI). Amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR–MET, has shown preclinical activity in TKI-sensitive EGFR-mutated NSCLC models and in an ongoing first-in-human study in patients with advanced NSCLC. However, the activity of amivantamab in Exon20ins-driven tumors has not yet been described. Ba/F3 cells and patient-derived cells/organoids/xenograft models harboring diverse Exon20ins were used to characterize the antitumor mechanism of amivantamab. Amivantamab inhibited proliferation by effectively downmodulating EGFR–MET levels and inducing immune-directed antitumor activity with increased IFNγ secretion in various models. Importantly, in vivo efficacy of amivantamab was superior to cetuximab or poziotinib, an experimental Exon20ins-targeted TKI. Amivantamab produced robust tumor responses in two Exon20ins patients, highlighting the important translational nature of this pre-clinical work. These findings provide mechanistic insight into the activity of amivantamab and support its continued clinical development in Exon20ins patients, an area of high unmet medical need. SIGNIFICANCE: Currently, there are no approved targeted therapies for EGFR Exon20ins–driven NSCLC. Preclinical data shown here, together with promising clinical activity in an ongoing phase I study, strongly support further clinical investigation of amivantamab in EGFR Exon20ins–driven NSCLC.

Original languageEnglish
Pages (from-to)1194-1209
Number of pages16
JournalCancer Discovery
Volume10
Issue number8
DOIs
Publication statusPublished - 2020

Bibliographical note

Funding Information:
This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning (NRF-2016R1A2B3016282 and 2018R1C1B6008916), Republic of South Korea.

Publisher Copyright:
© 2020 American Association for Cancer Research.

All Science Journal Classification (ASJC) codes

  • Oncology

Fingerprint

Dive into the research topics of 'Antitumor activity of amivantamab (Jnj-61186372), an egfr–met bispecific antibody, in diverse models of egfr exon 20 insertion–driven nsclc'. Together they form a unique fingerprint.

Cite this